Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Naif Khalaf Alharbi. (2019) Poxviral promoters for improving the immunogenicity of MVA delivered vaccines. Human Vaccines & Immunotherapeutics 15:1, pages 203-209.
Read now
Read now
Kaïdre Bendjama & Eric Quemeneur. (2017) Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer. Human Vaccines & Immunotherapeutics 13:9, pages 1997-2003.
Read now
Read now
Jonathan Pol, Norma Bloy, Florine Obrist, Alexander Eggermont, Jérôme Galon, Wolf Hervé Fridman, Isabelle Cremer, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch. OncoImmunology 3:4.
Read now
Read now
Houda Boukhebza, Nadine Bellon, Jean Marc Limacher & Geneviève Inchauspé. (2012) Therapeutic vaccination to treat chronic infectious diseases. Human Vaccines & Immunotherapeutics 8:12, pages 1746-1757.
Read now
Read now
Laurent Amiset, Laetitia Fend, Tania Gatard-Scheikl, Karola Rittner, Vanessa Duong, Ronald Rooke, Sylviane Muller, Jean-Yves Bonnefoy, Xavier Préville & Hélène Haegel. (2012) TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy. OncoImmunology 1:8, pages 1271-1280.
Read now
Read now
Channing J. Paller & Emmanuel S. Antonarakis. (2012) Sipuleucel-T for the treatment of metastatic prostate cancer. Human Vaccines & Immunotherapeutics 8:4, pages 509-519.
Read now
Read now
Stephen R Walsh & Raphael Dolin. (2011) Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Review of Vaccines 10:8, pages 1221-1240.
Read now
Read now
Kilian Guse, Vincenzo Cerullo & Akseli Hemminki. (2011) Oncolytic vaccinia virus for the treatment of cancer. Expert Opinion on Biological Therapy 11:5, pages 595-608.
Read now
Read now
Shifang Yuan, Changhong Shi, Li Liu & Wei Han. (2010) MUC1-based recombinant Bacillus Calmette–Guerin vaccines as candidates for breast cancer immunotherapy. Expert Opinion on Biological Therapy 10:7, pages 1037-1048.
Read now
Read now
Guus F Rimmelzwaan & Gerd Sutter. (2009) Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Review of Vaccines 8:4, pages 447-454.
Read now
Read now
Choon-Kit Tang, Maria Katsara & Vasso Apostolopoulos. (2008) Strategies used for MUC1 immunotherapy: human clinical studies. Expert Review of Vaccines 7:7, pages 963-975.
Read now
Read now
Choon-Kit Tang & Vasso Apostolopoulos. (2008) Strategies used for MUC1 immunotherapy: preclinical studies. Expert Review of Vaccines 7:7, pages 951-962.
Read now
Read now
Articles from other publishers (31)
Jinpeng Su, Livia Brunner, Edanur Ates Oz, Julia Sacherl, Geraldine Frank, Helene Anne Kerth, Frank Thiele, Marian Wiegand, Carolin Mogler, Julio Cesar Aguilar, Percy A. Knolle, Nicolas Collin, Anna D. Kosinska & Ulrike Protzer. (2023) Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models. Journal of Hepatology 78:4, pages 717-730.
Crossref
Crossref
Christin Schmidt, Mario Perkovic & Barbara S. Schnierle. (2021) Development of a Sensitive Detection Method for Alphaviruses and Its Use as a Virus Neutralization Assay. Viruses 13:7, pages 1191.
Crossref
Crossref
Daria Chulpanova, Valeriya Solovyeva, Kristina Kitaeva, Stephen Dunham, Svetlana Khaiboullina & Albert Rizvanov. (2018) Recombinant Viruses for Cancer Therapy. Biomedicines 6:4, pages 94.
Crossref
Crossref
Wei-Gang Hu, Robin Steigerwald, Marcus Kalla, Ariane Volkmann, David Noll & Les P. Nagata. (2018) Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses. Vaccine 36:34, pages 5194-5203.
Crossref
Crossref
Gilda G. Hillman, Lyndsey A. Reich, Shoshana E. Rothstein, Lisa M. Abernathy, Matthew D. Fountain, Kali Hankerd, Christopher K. Yunker, Joseph T. Rakowski, Eric Quemeneur & Philippe Slos. (2017) Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen. Journal for ImmunoTherapy of Cancer 5:1.
Crossref
Crossref
María Holgado, Juliana Falivene, Cynthia Maeto, Micaela Amigo, María Pascutti, María Vecchione, Andrea Bruttomesso, Gabriela Calamante, María del Médico-Zajac & María Gherardi. (2016) Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses. Viruses 8:5, pages 139.
Crossref
Crossref
Vasso Apostolopoulos. (2016) Vaccine Delivery Methods into the Future. Vaccines 4:2, pages 9.
Crossref
Crossref
Massimiliano Bissa, Elena Illiano, Sole Pacchioni, Francesca Paolini, Carlo Zanotto, Carlo De Giuli Morghen, Silvia Massa, Rosella Franconi, Antonia Radaelli & Aldo Venuti. (2015) A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers. Journal of Translational Medicine 13:1.
Crossref
Crossref
Christelle Remy-Ziller, Claire Germain, Anita Spindler, Chantal Hoffmann, Nathalie Silvestre, Ronald Rooke, Jean-Yves Bonnefoy & Xavier Préville. (2014) Immunological Characterization of a Modified Vaccinia Virus Ankara Vector Expressing the Human Papillomavirus 16 E1 Protein. Clinical and Vaccine Immunology 21:2, pages 147-155.
Crossref
Crossref
Philip J.R. Price, Lino E. Torres-Domínguez, Christine Brandmüller, Gerd Sutter & Michael H. Lehmann. (2013) Modified Vaccinia virus Ankara: Innate immune activation and induction of cellular signalling. Vaccine 31:39, pages 4231-4234.
Crossref
Crossref
Stephen R. Walsh, Marissa B. Wilck, David J. Dominguez, Elise Zablowsky, Shringkhala Bajimaya, Lisa S. Gagne, Kelly A. Verrill, Jane A. Kleinjan, Alka Patel, Ying Zhang, Heather Hill, Aruna Acharyya, David C. Fisher, Joseph H. Antin, Michael S. Seaman, Raphael Dolin & Lindsey R. Baden. (2013) Safety and Immunogenicity of Modified Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial. The Journal of Infectious Diseases 207:12, pages 1888-1897.
Crossref
Crossref
Catherine Fauvelle, Quentin Lepiller, Daniel J. Felmlee, Isabel Fofana, François Habersetzer, Françoise Stoll-Keller, Thomas F. Baumert & Samira Fafi-Kremer. (2013) Hepatitis C virus vaccines – Progress and perspectives. Microbial Pathogenesis 58, pages 66-72.
Crossref
Crossref
Alaina J Mooney & S Mark Tompkins. (2013) Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses. Future Virology 8:1, pages 25-41.
Crossref
Crossref
Antonia Radaelli, Carlo De Giuli Morghen, Carlo Zanotto, Sole Pacchioni, Massimiliano Bissa, Rosella Franconi, Silvia Massa, Francesca Paolini, Antonio Muller & Aldo Venuti. (2012) A prime/boost strategy by DNA/fowlpox recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated cancers. Virus Research 170:1-2, pages 44-52.
Crossref
Crossref
Elisa A. Nigro, Elisa Soprana, Anna T. Brini, Alessandro Ambrosi, Vijay A. Yenagi, David Dombrowicz, Antonio G. Siccardi & Luca Vangelista. (2012) An Antitumor Cellular Vaccine Based on a Mini-Membrane IgE. The Journal of Immunology 188:1, pages 103-110.
Crossref
Crossref
Lucile Tran, Jean-Paul Judor, Vanessa Gauttier, Michel Geist, Chantal Hoffman, Ronald Rooke, Georges Vassaux & Sophie Conchon. (2012)
The Immunogenicity of the Tumor-Associated Antigen
α
-Fetoprotein Is Enhanced by a Fusion with a Transmembrane Domain
. Journal of Biomedicine and Biotechnology 2012, pages 1-7.
Crossref
Crossref
Melanie Kremer, Asisa Volz, Joost H. C. M. Kreijtz, Robert Fux, Michael H. Lehmann & Gerd Sutter. 2012. Vaccinia Virus and Poxvirology. Vaccinia Virus and Poxvirology
59
92
.
Jenny J Kim, Daniel Keizman, Samuel R Denmeade & Emmanuel S Antonarakis. (2011) The unfolding treatment landscape for men with castration-resistant prostate cancer. Clinical Investigation 1:11, pages 1533-1544.
Crossref
Crossref
?ric Tartour, Federico Sandoval, Jean-Yves Bonnefoy & Wolf H. Fridman. (2011) Immunoth?rapie des cancers. m?decine/sciences 27:10, pages 833-841.
Crossref
Crossref
François Habersetzer, Géraldine Honnet, Christine Bain, Marianne Maynard–Muet, Vincent Leroy, Jean–Pierre Zarski, Cyrille Feray, Thomas F. Baumert, Jean–Pierre Bronowicki, Michel Doffoël, Christian Trépo, Delphine Agathon, Myew–Ling Toh, Martine Baudin, Jean–Yves Bonnefoy, Jean–Marc Limacher & Geneviève Inchauspé. (2011) A Poxvirus Vaccine Is Safe, Induces T-Cell Responses, and Decreases Viral Load in Patients With Chronic Hepatitis C. Gastroenterology 141:3, pages 890-899.e4.
Crossref
Crossref
Antonia Radaelli, Eleana Pozzi, Sole Pacchioni, Carlo Zanotto & Carlo De Giuli Morghen. (2010) Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits. Journal of Translational Medicine 8:1.
Crossref
Crossref
D.M.W. Zaiss, C.J.P. Boog, W. van Eden & A.J.A.M. Sijts. (2010) Considerations in the design of vaccines that induce CD8 T cell mediated immunity. Vaccine 28:49, pages 7716-7722.
Crossref
Crossref
Emmanuel S Antonarakis & Charles G Drake. (2010) Current status of immunological therapies for prostate cancer. Current Opinion in Urology 20:3, pages 241-246.
Crossref
Crossref
Robert Northrop. 2010. Signals and Systems Analysis In Biomedical Engineering, Second Edition. Signals and Systems Analysis In Biomedical Engineering, Second Edition
623
635
.
S. Backes, K. M. Sperling, J. Zwilling, G. Gasteiger, H. Ludwig, E. Kremmer, A. Schwantes, C. Staib & G. Sutter. (2009) Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2?. Journal of General Virology 91:2, pages 470-482.
Crossref
Crossref
Charles G. Drake. (2010) Immunotherapy for Prostate Cancer: An Emerging Treatment Modality. Urologic Clinics of North America 37:1, pages 121-129.
Crossref
Crossref
Matteo Vergati, Chiara Intrivici, Ngar-Yee Huen, Jeffrey Schlom & Kwong Y. Tsang. (2010) Strategies for Cancer Vaccine Development. Journal of Biomedicine and Biotechnology 2010, pages 1-13.
Crossref
Crossref
Michael H. Lehmann, Melanie Kremer, Yasemin Suezer & Gerd Sutter. 2010. The Challenge of Highly Pathogenic Microorganisms. The Challenge of Highly Pathogenic Microorganisms
245
251
.
Elisa A. Nigro, Antonio G. Siccardi & Luca Vangelista. 2010. Cancer and IgE. Cancer and IgE
215
229
.
Elisa A. Nigro, Anna T. Brini, Elisa Soprana, Alessandro Ambrosi, David Dombrowicz, Antonio G. Siccardi & Luca Vangelista. (2009) Antitumor IgE Adjuvanticity: Key Role of FcεRI. The Journal of Immunology 183:7, pages 4530-4536.
Crossref
Crossref
Lutz Gissmann & Karen Nieto. (2009) The Therapeutic Vaccine: Is it Feasible?. Archives of Medical Research 40:6, pages 493-498.
Crossref
Crossref